Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Nationwide Children's Hospital· Source
Recruiting
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source
Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· Phase 3· Charite University, Berlin, Germany· Source
Recruiting
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source
Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
NCT07630974· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
2025-521390-14-00· Phase 2· Pediatric Research International GmbH· Source
Recruiting
Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia.
2025-522138-29-00· Phase 2· Novartis Pharma AG· Source
Recruiting
Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery
2024-514089-37-00· Phase 2· The University Of Birmingham· Source
Recruiting
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
NCT07570173· Phase 2/3· Merck Sharp & Dohme LLC· Source
Not yet recruiting
THRILL: Treat Hyperinflammation in child oncology study
2025-524541-27-00· Phase 2· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source
Not yet recruiting
FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide – an exploratory pilot and feasibility trial
2025-520814-78-00· Phase 1/2· Universitair Medisch Centrum Utrecht· Source
Active, not recruiting
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
NCT07134088· Phase 1/2· Amgen· Source
Recruiting
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
NCT07223021· Phase 3· Memorial Sloan Kettering Cancer Center· Source
Recruiting
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05745714· Phase 1/2· Princess Maxima Center for Pediatric Oncology· Source
Recruiting
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05751044· Phase 1/2· Princess Maxima Center for Pediatric Oncology· Source
Not yet recruiting
The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies
NCT07020260· Phase 1/2· Princess Maxima Center for Pediatric Oncology· Source
Recruiting
A study to determine how safe MB-CART2019.1 is and how well it works in children and adolescents with B cell neoplasms
NCT06508951· Phase 2· Miltenyi Biomedicine GmbH· Source
Recruiting
VyClo ITCC-092
2023-508050-26-00· Phase 1· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source
Recruiting
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
NCT06941272· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
NCT06376162· Phase 1· PedAL BCU, LLC· Source
Recruiting
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
NCT06485947· Phase 1· Princess Maxima Center for Pediatric Oncology· Source
Active, not recruiting
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
NCT02205762· Phase 2/3· St. Anna Childrens Cancer Research Institute GmbH· Source
Active, not recruiting
A study to investigate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared with standard of care with allogeneic hematopoietic stem cell transplantation (allo-HSCT)
2022-500306-17-00· Phase 3· Orchard Therapeutics (Europe) Limited· Source
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
NCT05991388· Phase 2/3· University of Birmingham· Source
Recruiting
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
NCT06262438· Phase 2· Princess Maxima Center for Pediatric Oncology· Source
Recruiting
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
NCT05658640· Phase 1/2· Princess Maxima Center for Pediatric Oncology· Source
Recruiting
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
2023-504999-25-00· Phase 3· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source
Active, not recruiting
Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma
NCT05830084· Phase 1· Gustave Roussy, Cancer Campus, Grand Paris· Source
Recruiting
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
NCT05748171· Phase 2· Pfizer· Source
Active, not recruiting
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source
Active, not recruiting
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
NCT05183035· Phase 3· PedAL BCU, LLC· Source
Active, not recruiting
Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemia.
2023-508129-28-00· Phase 1/2· Novartis Pharma AG· Source
Recruiting
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
NCT05465174· Phase 2· Sabine Mueller, MD, PhD· Source
Recruiting
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
NCT04925609· Phase 1/2· Princess Maxima Center for Pediatric Oncology· Source
Recruiting
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
2024-510578-25-00· Phase 3· The University Of Birmingham· Source
Recruiting
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
NCT04732065· Phase 1· Sabine Mueller, MD, PhD· Source
Recruiting
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
NCT04903899· Phase 2· Jakob Stenman· Source
Recruiting
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485· Phase 2· Day One Biopharmaceuticals, Inc.· Source
Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04625907· Phase 1/2· University of Birmingham· Source
Recruiting
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576· Phase 3· Mats Heyman· Source
Active, not recruiting
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
NCT04258943· Phase 1/2· Children's Oncology Group· Source
Recruiting
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
NCT03838042· Phase 1/2· University Hospital Heidelberg· Source
Recruiting
Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study)
2023-506546-23-00· Phase 3· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source
Recruiting
SIOP RANDOMET 2017
2023-508926-91-00· Phase 3· GPOH gGmbH· Source
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source
Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399· Phase 1/2· Syndax Pharmaceuticals· Source
Recruiting
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
NCT04793919· Phase 2· Associazione Italiana Ematologia Oncologia Pediatrica· Source
Recruiting
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494· Phase 3· University Hospital Muenster· Source
Active, not recruiting
Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours
2023-507582-25-00· Phase 3· Rheinische Friedrich-Wilhelms-Universitaet Bonn· Source
Showing 50 of 65.